European Biotechnology Magazine

Sensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech is discontinuing development of its OTOF-targeted therapy SENS-501, citing a changed competitive environment following the approval of Regeneron’s rival gene therapy.

Orionis and Novartis have expanded an existing deal to develop “molecular glue”, with a new agreement worth up to $1.4 billion, aiming to stick small molecule drugs onto challenging and elusive drug targets.

The post

Veraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading as of today on the Nasdaq under the ticker symbol VRXA. For the company, which has roots in the Heidelberg region, the move marks its transition from a research-driven company to ...

Scenic Biotech has joined the Michael J. Fox Foundation's LRRK2 consortium to test a Parkinson's disease approach that targets neither LRRK2 nor GCase directly.

The post Scenic...

Sanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, the latest setback raises fresh questions about whether the Bioverativ pipeline can justify its price tag.

The post